Introduction
Recently, the mechanism mediating the active iodide transport across the basolateral membrane of thyroid follicular cells has been clarified by cloning and characterization of the sodium iodide symporter (NIS). [1] [2] [3] NIS, which is an intrinsic membrane glycoprotein with 13 putative transmembrane domains, is responsible for the ability of the thyroid gland to transport and concentrate iodide, approximately 20-to 40-fold above plasma concentration. 4, 5 Its expression in thyroid cancer cells allows effective therapy with radioiodine, even in advanced disease with distant metastasis, and this therapy contributes to improved progosis of these patients. 6 A novel form of cytoreductive cancer gene therapy, using NIS gene transfer to induce radioiodine accumulation activity in cancer cells, would therefore extend the application of carrierfree radioiodine and the extensive experience with radioiodine in thyroid cancer therapy to the treatment of non-thyroidal cancer. [7] [8] [9] [10] Because no curative therapy exists for metastatic prostate cancer, which represents the second leading cause of cancer death in men, 11 novel therapeutic strategies are urgently needed. We have chosen prostate cancer for these reasons as the tumor model to explore the utility of NIS gene transfer as a first step towards radioiodine therapy of non-thyroidal tumors.
We recently reported the induction of tissue-specific androgen-dependent iodide uptake activity in prostate cancer cells in vitro by liposome-mediated NIS gene delivery. 12 The androgen-sensitive human prostatic adenocarcinoma cell line LNCaP stably transfected with the human NIS gene under the control of the prostatespecific antigen (PSA) promoter revealed androgendependent and prostate-specific iodide uptake activity, that was high enough to allow a therapeutic response of accumulated 131 I in vitro, as well as in vivo. 12, 13 While these data obtained with a cloned LNCaP cell line stably expressing NIS and therefore revealing maximum NIS expression levels, demonstrated the potential of NIS as a novel therapeutic gene in the therapy of prostate cancer, they are not directly applicable for clinical use in humans. As a next crucial step towards clinical application of NIS gene transfer followed by radioiodine therapy in prostate cancer patients, the aim of our current study was to perform adenovirus-mediated in vivo NIS gene delivery in prostate cancer xenografts and examine its capacity to induce accumulation of therapeutically effective doses of radioiodine. For this purpose a replication-deficient human adenovirus carrying the human NIS (hNIS) gene linked to the CMV promoter (Ad5-CMV-NIS) was developed. The results reported herein clearly demonstrate the potential efficacy of radioiodine therapy of nonthyroid tumors, in particular prostate cancer, following NIS gene transfer.
Results
Iodide uptake studies in vitro Four days following adenoviral infection, Ad5-CMV-NISinfected LNCaP cells revealed a 10-fold increase in iodide accumulation compared with Ad5-CMV-NIS-infected LNCaP cells co-incubated with perchlorate and a 20-fold increase compared with LNCaP cells infected with a control virus (P Ͻ 0.01) (Figure 1a) . Maximum iodide accumulation representing the maximum level of functional NIS protein expression was reached 4 days following adenoviral infection (Figure 1b) . Gene Therapy cell xenografts by Western blot analysis using a mouse monoclonal antibody that recognizes the carboxy-terminus of hNIS. Western blotting of membrane proteins derived from Ad5-CMV-NIS-infected xenografts revealed a band of a molecular weight of approximately 90 kDa (consistent with previously reported NIS protein 14 ), which was not detected in xenografts infected with control virus (Figure 2 ).
Western blot analysis

Immunohistochemical staining
Immunostaining of paraffin-embedded tissue sections derived from LNCaP cell xenografts was performed 4 days following injection with Ad5-CMV-NIS or control virus using a mouse monoclonal hNIS antibody. Generalized, predominantly cell membrane-associated hNISspecific immunoreactivity was detected in an average of 80% of the cells in LNCaP xenografts infected with Ad5-CMV-NIS, with most prominent staining near the injection sites (Figure 3a, arrows) . In contrast, LNCaP xenografts infected with control virus did not show hNISspecific immunoreactivity (Figure 3b ). Control slides stained with primary and secondary antibodies replaced in turn by PBS and isotype-matched nonimmune mouse immunoglobulin were consistently negative (Figure 3c control vector (left flank) was performed. Four days following adenovirus injection, mice (n = 4) were given 500 Ci 123 I by intraperitoneal injection, and radioiodine uptake by the tumors was monitored and quantified by imaging with a gamma camera. In contrast to the left flank control tumors, which showed no in vivo uptake of radioiodine, right flank tumors accumulated 20.2 ± 11.4% of the total radioiodine dose administered ( Figure 4 ). The average biological half-life of accumulated radioiodine in LNCaP cell xenotransplants as determined by serial imaging over 48 h was 5.6 ± 1.4 h ( Figure 5 ).
Radioiodine therapy study in vivo
LNCaP cell xenografts were established in two groups of mice (six mice in each group) as described above. Following 6 to 8 weeks of tumor growth (average tumor diameter 5 mm), one group of mice (therapy group) was administered 3 mCi 131 I (111 MBq) by a single intraperitoneal injection, while the second group of mice (control group) was administered saline. Tumor measurements were made before administration of radioiodine and weekly thereafter. All mice were followed for a total of 6 weeks. As demonstrated in Figure 6 
Discussion
The sodium iodide symporter (NIS) is an intrinsic membrane protein that mediates the active iodide uptake across the basolateral membrane of benign and malignant thyroidal cells. [1] [2] [3] 15 The unique property of thyroidal cells to trap and concentrate iodide due to expression of NIS allows imaging and highly effective therapy of differen- 
I scan of a mouse harboring LNCaP cell xenografts 24 h following intraperitoneal injection of 500 Ci I. Four days following intratumoral injection of Ad5-CMV-NIS (right hip) or control virus (left hip), Ad5-CMV-NIS-infected tumors trapped 20.2 ± 11.4% of the total radioiodine administered (right), while control virus-infected tumors showed no radioiodine uptake (left).
123 I was also accumulated physiologically in bladder, stomach and the thyroid gland. Gene Therapy
Figure 6 Radioiodine therapy study in vivo. Growth of Ad5-CMV-NISinfected LNCaP tumors (solid symbols) and control vector-infected LNCaP tumors (open symbols) in nude mice following injection of 3 mCi 131 I (solid lines) or saline (dashed lines).
tiated thyroid carcinomas and their metastases by administration of radioiodine. Cloning and characterization of the NIS gene therefore offers the possibility of a novel cytoreductive gene therapy strategy based on NIS gene transfer into non-thyroidal tumor cells followed by radioiodine therapy. 10 who expressed the rat NIS gene in several tumor cell lines (cervix, prostate, breast, lung and colon carcinoma cells) by adenovirus-mediated gene transfer and were able to demonstrate radioiodine uptake, as well as a selective cytotoxic effect of trapped radioiodine in vitro. Following in vivo NIS gene delivery, cervix and breast cancer xenografts in nude mice also revealed radioiodine accumulation in vivo, that, however, did not result in a therapeutic effect of 131 I. While these data show the utility of NIS gene transfer using viral, as well as non-viral vectors to induce radioiodine accumulation in non-thyroidal tumor cells, the therapeutic effect of accumulated 131 I could not be confirmed. Prostate cancer represents the most common cancer and the second highest cause of cancer death in men in Western society. 16 Currently available therapies, including prostate surgery and targeted irradiation can cure only local disease, while recurrent and metastatic prostate cancer have a poor survival rate. Novel therapeutic approaches, such as gene therapy, are therefore clearly required. A variety of gene therapy strategies for prostate cancer have been examined in recent years, such as corrective gene therapy aimed at restitution of normal tumor suppressor gene function, cytoreductive gene therapy including the herpes simplex virus thymidine kinase and ganciclovir system, ablative gene therapy, in particular antisense oligonucleotides directed against oncogenes, and immunomodulatory gene therapy. 17 The fact that the prostate gland, similar to the thyroid gland, represents a 'dispensible' organ, therapeutic strategies, including NIS gene transfer that kill malignant, as well as benign, prostate cells can be pursued.
In an earlier study, using a liposome-mediated gene delivery technique we explored the efficacy of NIS gene transfer to induce accumulation, as well as a therapeutic effect of 131 I in stably transfected prostate cancer cells. 12, 13 To limit radioiodine accumulation to prostate cancer cells thereby minimizing extratumoral cytotoxicity, we used the PSA promoter to target NIS gene expression to prostate cells. [18] [19] [20] [21] Prostate cell-specific, androgen-regulated iodide uptake activity was demonstrated in LNCaP cell lines stably expressing NIS under the control of the PSA promoter in vitro and in vivo. Further, the amount of accumulated 131 I was shown to be sufficiently high to selectively kill NIS-transfected LNCaP cells in vitro, as well as in vivo in stably transfected LNCaP cell xenografts. 12, 13 Administration of a single therapeutic 131 I dose of 3 mCi was able to elicit a dramatic therapeutic response in NIS-transfected LNCaP cell xenografts, which accumulated 25-30% of the total administered radioiodine dose, with an average volume reduction of 80-90% and complete tumor regression in up to 60% of the tumors. 13 As a next crucial step towards therapeutic application of NIS gene delivery followed by radioiodine therapy in prostate cancer patients in a clinical setting, in the current study we performed in vivo NIS gene transfer into LNCaP cell tumors using a replication-deficient human adenovirus carrying the human NIS gene linked to the CMV promoter (Ad5-CMV-NIS) and examined radioiodine accumulation and therapeutic effectiveness of 131 
I in vivo.
We chose to use a recombinant adenovirus serotype 5 vector for our experiments as these vectors have been shown to achieve highly efficient in vivo gene transfer upon intratumoral administration due to the high titers they can produce and their ability to infect non-dividing cells. 22 In addition, using adenoviral vectors efficient in vivo gene transfer has been demonstrated in numerous tissue types, including prostate tissue. 23 LNCaP tumors injected with Ad5-CMV-NIS accumulated 20.2 ± 11.4% of the total radioiodine dose administered with an average biological half life of 5.6 ± 1.4 h. Further, NIS protein expression in LNCaP cell xenografts was confirmed by Western blot analysis and immunohistochemistry using a mouse monoclonal NIS-specific antibody. Following intraperitoneal injection of a single therapeutic dose of 3 mCi 131 I 4 days after adenovirus-mediated intratumoral NIS gene delivery, LNCaP xenografts showed a clear therapeutic response with an average volume reduction of 84 ± 12%. Although, compared with our earlier study in a cloned LNCaP cell line, 13 in vivo NIS gene transfer into LNCaP xenografts resulted in slightly lower amounts of accumulated radioiodine and a significantly shorter biological half-life of 131 I, a dramatic therapeutic effect of accumulated 131 I was observed. These data suggest that the intratumoral radioiodine concentration was high enough to compensate the lower biological half-life, thereby achieving a therapeutically effective radiation dose in LNCaP cell tumors. In addition, the energy emitted by 131 I accumulated in NIS expressing cells through beta-particles may result in a substantial bystander killing of adjacent untransfected cells further enhancing the therapeutic response to radioiodine.
In the thyroid gland, following transport of iodide across the apical membrane into the colloid by pendrin, the Pendred syndrome gene product, 24 iodide is oxidized and incorporated into tyrosyl residues along the thyroglobulin (Tg) backbone. This complex reaction at the cell/colloid interface is termed iodide organification and is catalyzed by thyroid peroxidase (TPO). 15 The term organification refers to the incorporation of iodide into organic molecules, that results in an increased retention time of trapped iodide in the thyroid gland. Although this iodide organification in thyroid follicular cells is generally believed to represent a crucial prerequisite for radioiodine therapy of thyroid cancer, no clear data exist to prove this assumption. In fact, it has been shown that even thyroid carcinomas and their metastases often reveal a diminished ability of iodide organification and thyroid hormone synthesis due to disrupted follicular architecture and function, and lack of thyroglobulin expression. 25, 26 Because accumulated radioiodine is not organified in LNCaP cells (data not shown), our present data suggest that iodide organification is not required to achieve a therapeutic effect of radioiodine in tumor tissue. Organification of trapped radioiodine is certainly capable of increasing the achieved radiation dose by enhancing retention time and biological half-life of radioiodine in the target tissue, and might be used therapeutically in non-organifying tissues by coupling of NIS gene transfer with the delivery of the TPO or Tg gene. In addition, lithium has been shown to reduce iodide efflux from thyroidal cells, thereby increasing radioiodine retention and enhancing therapeutic efficacy of radioiodine in the treatment of Graves' hyperthyroidism. 27, 28 If further studies can show that lithium also reduces iodide efflux in non-thyroidal, non-organifying tumors, it could be used as a potential adjuvant to 131 I therapy of nonthyroidal tumors following NIS gene transfer. In our study, however, an adenovirus-mediated NIS gene delivery system provides an effective way to reach a radiation dose that allows a therapeutic effect of 131 I in nonorganifying tumors by achieving high levels of radioiodine accumulation.
Since the ultimate goal of this project is to selectively kill prostate cancer cells by in vivo NIS gene delivery thereby eliminating extratumoral cytotoxicity, we have begun to develop adenoviral vectors carrying the NIS gene linked to the PSA or other prostate-specific promoters. For this purpose, as the packaging capacity of adenoviruses is limited, PSA promoter fragments shorter than the 6 kb PSA promoter fragment used in our earlier study 12, 18 but still capable of confering maximal tissuespecificity in vitro and in vivo need to be developed and characterized.
In conclusion, a therapeutic effect of 131 I has been demonstrated in prostate cancer cell tumors in vivo following in vivo NIS gene delivery. This study clearly demonstrates the potential of NIS as a novel therapeutic gene for in vivo gene therapy of non-thyroidal cancers, in particular prostate cancer.
Materials and methods
Cell culture
The human prostatic adenocarcinoma cell line LNCaP (passage 20-40) was grown in RPMI 1640 medium (Life Technologies, Gaithersburg, MD, USA) containing penicillin G (2 units/ml)/streptomycin sulfate (100 mg/ml) (Life Technologies) and 10% fetal bovine serum (Life Technologies). Cells were free of mycoplasma and used in the log phase of growth. Cells were routinely harvested using 0.05% trypsin (Life Technologies).
Recombinant adenovirus production
Replication-deficient human recombinat type 5 adenovirus (Ad5) carrying the human NIS gene linked to the CMV promoter were developed in collaboration with the Gene Transfer Vector Core Facility of the University of Iowa (Iowa City, IA, USA). The human NIS cDNA was cut from the pcDNA3 plasmid (kindly provided by Sissy M Jhiang, Ohio State University, Columbus, OH, USA) using HindIII and NotI and cloned into pAd5CMVK-NpA. The resulting plasmid was co-transfected into 293 cells with near full-length adenoviral DNA previously restricted to remove a portion of the E1 region. Following transfection, plaques were harvested and lysates prepared by three rounds of freeze/thawing. Lysates were then used to infect 100 mm plates of 293 cells. After the complete cytopathic effect, cells were harvested, lysed by freeze/thawing and functional analysis was performed by measurement of iodide uptake in transfected LNCaP cells (see below). Following two more rounds of plaque purification the resulting recombinant adenovirus (Ad5-CMV-NIS) was expanded in 293 cells and purified by banding on CsCl density gradients, followed by dialysis.
Nude mice
Male BALB/c nu/nu mice at 6-8 weeks of age were purchased from Harlan Sprague-Dawley (Indianapolis, IN, USA) and maintained in our facility under specific pathogen-free conditions with access to mouse chow and water ad libitum. All experiments were performed in accordance with the IACUC guidelines of the Mayo Clinic (Rochester, MN, USA).
Adenovirus-mediated NIS gene delivery in LNCaP cells in vitro
LNCaP cells plated on six-or 12-well plates (1 × 10 5 cells/ml) were washed and incubated with OptiMEM (Life Technologies) containing Ad5-CMV-NIS (MOI = 30) for 3 h. Medium was replaced by fresh culture medium and virus-infected LNCaP cells were further maintained for 2-6 days, before iodide accumulation was measured to determine levels of functional NIS protein expression.
Iodide uptake studies in vitro Uptake of 125 I by virus-infected LNCaP cells was determined at steady-state conditions as described by Weiss et al. 29 In brief, 2-6 days following infection, iodide uptake studies were performed in Hank's balanced salt solution (HBSS) supplemented with 10 m NaI, 0.1 Ci Na 125 I/ml and 10 mm Hepes at pH 7.3. 100 m KClO 4 was added to control wells. Trapped iodide was removed from cells by a 20 min incubation in 1 N NaOH and measured by ␥-counting.
Adenovirus-mediated NIS gene delivery in LNCaP cell xenografts in vivo
Xenotransplants derived from LNCaP cells were established in male BALB/c nude mice (both flanks) by subcutaneous injection of 1 × 10 6 cells suspended in 0.25 ml RPMI-1640 medium and 0.25 ml Matrigel Basement Membrane Matrix (Becton Dickinson, Bedford, MA, USA). 30 Following 6-8 weeks of tumor growth when the tumor volume became palpable and measurable by caliper (approximately 5 × 5 mm) and mice had received a low-iodine diet and T4 supplementation (5 mg/l) in their drinking water for 2 weeks to maximize radioiodine uptake in the tumor and reduce iodide uptake by the thyroid gland, animals were anesthesized with ketamine (100 mg/kg) and xylazine (10 mg/kg). Thereafter, a total volume of 150 l (3 × 10 9 p.f.u./ml in 3% sucrose/ phospate buffered saline) of a recombinant Ad5-CMV-NIS (right flank) or control virus Ad5-CMV (kindly provided by Tim O'Brien, Department of Endocrinology, Mayo Clinic, Rochester, MN, USA) (left flank) was injected at five different injection sites directly into the tumors using tuberculin syringes with a 28-gauge .-inch needle. The needle was moved to various sites within the tumor during injection to maximize the area of virus exposure.
Membrane preparation
Membrane proteins were prepared from LNCaP cell xenografts by a modification of a previously described procedure. 31 In brief, LNCaP cell tumors were dissected and homogenized in buffer A (250 mm sucrose; 10 mm TrisHCl, pH 7.5; 1 mm MgCl 2 ; 40 mg/l aprotinin; 1 mm PMSF; 4 mg/l leupeptin). The homogenate was centrifuged at 1500 g for 5 min at 4°C. Following centrifugation, 100 l 1 m Na 2 CO 3 per ml buffer A was added to the supernatant and incubated at 4°C for 45 min with continuous shaking. Further centrifugation at 100 000 g was performed for 15 min, and the pellet was resuspended in an appropriate volume of buffer A. Protein concentrations were determined by a protein assay (BioRad DC Protein Assay; BioRad, Hercules, CA, USA).
Western blot analysis
For Western blot analysis, the NuPAGE electrophoresis system (NOVEX, San Diego, CA, USA) was used. Aliquots of membranes (20 g) prepared from LNCaP cell xenografts were reduced by incubation with 0.5 m DTT for 10 min at 70°C and loaded on 4-12% Bis-Tris-HCl buffered polyacrylamide gels. Following gel electrophoresis for 1 h, proteins were transferred to nitrocellulose membranes using electroblotting. Following blotting, membranes were preincubated for 1 h in 5% low fat dried milk in TBS-T (20 mm Tris, 137 mm NaCl and 0.1% Tween-20) to block nonspecific binding sites. Membranes were then incubated with a mouse monoclonal antibody directed against amino acid residues 468-643 of human NIS (dilution 1:3000) 14 for 2 h at room temperature. After washing with TBS-T, horseradish peroxidase-labelled goat-anti-mouse-antibody was applied (dilution 1:5000) for 1 h at room temperature before incubation with ECL Western blotting detection reagents (Amersham, Arling-ton Heights, IL, USA) for 1 min. Exposures were made at room temperature for approximately 1 min using Kodak BIOMAX MR films. Prestained protein molecular weight standards (Life Technologies) were run in the same gels for comparison of molecular weight and estimation of transfer efficiency.
Immunohistochemistry
Immunohistochemical staining of paraffin-embedded tissue sections derived from LNCaP cell xenografts was performed using the Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA). Tissue sections were deparaffinized by serial passages in xylene, then subjected to a graded series of ethanol washes, before endogenous peroxidase activity was blocked by incubation in a 50% by volume solution of 3% H 2 O 2 /methanol for 10 min. Subsequently, slides were pretreated by heating in citrate buffer (10 mm citric acid) for 30 min. Following blocking of nonspecific binding with blocking serum for 30 min, slides were incubated with mouse monoclonal hNIS antibody (directed against amino acid residues 468-643 of hNIS) at a dilution of 1:2000 14 for 90 min. Tissue sections were washed and incubated with biotin-conjugated anti-mouse-immunoglobulin for 30 min at room temperature, followed by incubation with preformed avidin and biotinylated horseradish peroxidase macromolecular complex. Diaminobenzidine (DAB) was used as the chromogen, and yielded a bluish-black precipitate indicative of hNIS-like immunoreactivity. Slides were counterstained with malachite green for 5 min before mounting. Parallel monolayers with the primary and secondary antibodies replaced in turn by PBS and isotype matched non-immune IgGs were examined to assure specificity, and to exclude crossreactivities between the antibodies and conjugates employed.
Iodide uptake studies in vivo
Four days following intratumoral injection of Ad5-CMV-NIS (right flank) or control virus (left flank), mice were injected intraperitoneally with 500 Ci 123 I and radioiodine imaging was performed using a gamma camera equipped with a low energy general-purpose collimator (Helix System; Elscint, Haifa, Israel). Regions of uptake have been quantified and expressed as a fraction of the total amount of the applied radioiodine. Iodide retention time within the tumor was determined by serial scanning following radioiodine injection.
Radioiodine therapy study in vivo
Xenografts of LNCaP cells were established in two groups of mice (six mice in each group, average tumor volume 5 × 5 mm) as described above. Two weeks before radioiodine administration mice were switched to a lowiodine diet and received T4 supplementation (5 mg/l) in their drinking water to maximize radioiodine uptake in the tumor and reduce uptake by the thyroid gland. Four days following intratumoral injection of Ad5-CMV-NIS (right flank) or control virus (left flank), one group of mice (therapy group) was administered 3 mCi 131 I by a single intraperitoneal injection, while the second group of mice (control group) was administered saline. Tumors were measured before administration of radioiodine and weekly thereafter. Tumor volume was estimated using the formula: tumor volume = length × width × height × 0.52. 32 All mice were followed for a total of 6 weeks. Tumor volumes of right flank tumors (Ad5-CMV-NIS) in the therapy group were compared with tumor volumes of left flank tumors (control virus) in the therapy group and tumor volumes of right and left flank tumors in the control groups. Statistical significance was tested using Student's t test (for unpaired samples when examining between treated and untreated mice and for paired samples when examining tumors within the same mouse).
